Takeo Satoshi, Tanonaka Kouichi
Department of Molecular and Cellular Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.
Cardiovasc Drug Rev. 2006 Spring;24(1):51-62. doi: 10.1111/j.1527-3466.2006.00051.x.
Na(+) channel blockade is thought to be involved in the cardioprotection against ischemia/reperfusion injury. We synthesized various cyclohexane dicarboximides and examined their cardioprotective actions. Some of these derivatives had local anesthetic action and were capable of enhancing post-hypoxic contractile recovery of the isolated perfused rat heart. Among them, 2-[4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]butyl]hexahydro-1H-isoindol-1,3(2H)-dione hydrochloride (ST-6) was most effective in the enhancement of post-hypoxic contractile recovery of isolated perfused rat hearts subjected to 20-min hypoxia and 45-min reoxygenation. This enhanced recovery by 30 mg/min of ST-6 was associated with attenuation of Na(+), but not of Ca(2+), accumulation during ischemia and prevention of creatine kinase release from the heart during reperfusion. When hearts subjected to 30-min ischemia followed by 60-min reperfusion were pretreated with 30 muM ST-6, the post-ischemic contractile recovery was enhanced and ischemia-induced accumulation of Na(+), as well as reperfusion-induced accumulation of Na(+) and Ca(2+), was attenuated. Also the reperfusion-induced release of creatine kinase was reduced, while restoration of myocardial high-energy phosphates was enhanced during reperfusion. Na(+) channel blockade by ST-6, as assessed by the depression of the Vmax of the action potential, was similar to that produced by flecainide but more pronounced than with either lidocaine or disopyramide. ST-6, 1, or 2 mg/kg i.v. or 10 mg/kg i.p., abolished ventricular fibrillation induced by 4 min of ischemia and subsequent 4 min of reperfusion in rats. The prevention of ventricular fibrillation by the continuous injection of 0.2 mg/kg per min ST-6 from the first min after ischemia to the end of reperfusion was similar in degree to that produced by 0.1 mg/kg/min lidocaine or 0.5 mg/kg/min diltiazem. The former treatment elicited a transient decrease in the systemic blood pressure in anesthetized rats during ischemia, whereas treatment with the latter did not reduce systemic blood pressure. These findings suggest that ST-6 may have cardioprotective effects in ischemia/reperfusion injury.
钠通道阻滞被认为与对抗缺血/再灌注损伤的心脏保护作用有关。我们合成了多种环己烷二羧酸亚胺,并研究了它们的心脏保护作用。其中一些衍生物具有局部麻醉作用,能够增强离体灌注大鼠心脏缺氧后的收缩恢复。在这些衍生物中,2-[4-[4-(4-氯苯基)-4-羟基-1-哌啶基]丁基]六氢-1H-异吲哚-1,3(2H)-二酮盐酸盐(ST-6)在增强经历20分钟缺氧和45分钟复氧的离体灌注大鼠心脏缺氧后的收缩恢复方面最为有效。ST-6以30毫克/分钟的剂量增强恢复与缺血期间钠(而非钙)积累的减轻以及再灌注期间心脏肌酸激酶释放的预防有关。当对经历30分钟缺血后再灌注60分钟的心脏用30微摩尔/升的ST-6进行预处理时,缺血后收缩恢复增强,缺血诱导的钠积累以及再灌注诱导的钠和钙积累均减轻。此外,再灌注诱导的肌酸激酶释放减少,而再灌注期间心肌高能磷酸盐的恢复增强。通过动作电位Vmax的降低评估,ST-6对钠通道的阻滞作用与氟卡尼产生的作用相似,但比利多卡因或丙吡胺更明显。静脉注射1或2毫克/千克或腹腔注射10毫克/千克的ST-6可消除大鼠4分钟缺血及随后4分钟再灌注诱导的心室颤动。从缺血后第一分钟到再灌注结束以0.2毫克/千克/分钟的速度持续注射ST-6预防心室颤动的程度与以0.1毫克/千克/分钟的利多卡因或0.5毫克/千克/分钟的地尔硫䓬产生的程度相似。前一种处理在缺血期间使麻醉大鼠的全身血压短暂下降,而后一种处理则不会降低全身血压。这些发现表明ST-6在缺血/再灌注损伤中可能具有心脏保护作用。